Pharmacology and metabolism of @entity25928 , XXXX and @entity1331 in the treatment of invasive candidosis: review of the literature.

@entity1331 @entity1 @entity25928 @entity6923 @entity2379 @entity2380 @entity18203 @entity7409 @entity5626 @entity99 @entity11794
@entity5626 represent the newest class of antifungal agents. Currently, three @entity5626 , @entity25928 , @entity11794 and @entity1331 are licensed for clinical use in various indications. They act as inhibitors of b-(1,3)-glucan synthesis in the fungal cell wall and have a favorable pharmacological profile. They have a broad spectrum of activity against all Candida species. Higher MIC's have been observed against @entity7409 and @entity18203 . Data from clinical trials for invasive @entity6923 suggest that the clinical outcome of @entity1 treated with either drug may be very similar. A comparison has been done between @entity11794 and @entity1331 but for @entity25928 a comparative trial with another echinocandin is still lacking. All three drugs are highly effective if not superior to treatment with either @entity2380 or @entity2379 , particularly in well-defined clinical settings such as invasive @entity6923 , @entity6923 and candidaemia. Differences between the three @entity5626 with regard to the route of metabolism, requirement for a loading dose, dose adjustment in @entity1 with moderate to severe @entity99 and different dosing schedules for different types of @entity6923 have to be considered. Relevant drug-drug interactions of @entity11794 and @entity1331 are minimal. @entity25928 has no significant drug interactions at all. However, @entity5626 are available only for intravenous use. All three agents have an excellent safety profile.
